{"id":7341,"date":"2026-06-11T15:50:22","date_gmt":"2026-06-11T15:50:22","guid":{"rendered":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/?p=7341"},"modified":"2026-06-11T15:50:22","modified_gmt":"2026-06-11T15:50:22","slug":"highly-effective-prevention-drug-arrives-in-south-africa-which-has-worlds-highest-hiv-burden","status":"publish","type":"post","link":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/2026\/06\/11\/highly-effective-prevention-drug-arrives-in-south-africa-which-has-worlds-highest-hiv-burden\/","title":{"rendered":"Highly effective prevention drug arrives in South Africa, which has world\u2019s highest HIV burden"},"content":{"rendered":"\n

https:\/\/apnews.com\/article\/south-africa-hiv-prevention-drug-lenacapavir-f243eb90c0bc6e595c8efa527e7c6b23<\/a><\/p>\n\n\n\n

South Africa is home to more people living with HIV than any other country in the world, over 8 million, and for decades, the standard prevention method has been a daily oral pill that many people struggle to take consistently. That may be changing. In June 2026, South Africa became one of the first countries to officially roll out lenacapavir, a twice-yearly injectable drug that clinical trials showed to be 100% effective at preventing HIV infection. For young people like 19-year-old Olwam Plaatjie, who grew up watching family members suffer from the virus, the drug represents something powerful: a realistic, manageable way to stay protected without the daily reminder of a pill.<\/p>\n\n\n\n

From an international relations standpoint, the story of lenacapavir’s rollout is complicated. The drug was developed by the American pharmaceutical company Gilead Sciences, and much of the clinical trial work that proved its effectiveness was done in South Africa and Uganda, meaning African communities bore significant risk and contributed essential data to bring this drug to the world. Yet South Africa only received enough doses for 456,000 people, funded by a $29 million Global Fund grant, while health advocates argue at least 2 million doses per year are needed to meaningfully reduce infection rates. This imbalance raises a familiar tension in global health: who controls access to life-saving medicines, and do the communities that helped develop them get first priority?<\/p>\n\n\n\n

The situation is further complicated by the United States’ decision to cut foreign aid, which forced the closure of 12 HIV clinics in South Africa that served some of the most vulnerable populations, including sex workers, drug users, and transgender people who are unlikely to seek care at standard public facilities. This is a direct consequence of shifting U.S. foreign policy priorities, and it illustrates how decisions made in Washington can have immediate, life-or-death consequences thousands of miles away. Where American support has pulled back, organizations and governments are scrambling to fill the gap, but the loss of safe, confidential spaces for high-risk groups is not easily replaced.<\/p>\n\n\n\n

In the end, lenacapavir’s arrival in South Africa is both a genuine breakthrough and a reminder of how unequal global health systems remain. A drug that could virtually eliminate new HIV infections exists, but whether it reaches the people who need it most depends on negotiations between pharmaceutical companies, international donors, and national governments. South Africa’s role in developing this drug while fighting for adequate access to it captures a much wider story about power, equity, and whose lives global medicine is actually designed to protect. The science has delivered a solution; now the harder work of delivering it fairly has just begun.<\/p>\n","protected":false},"excerpt":{"rendered":"

https:\/\/apnews.com\/article\/south-africa-hiv-prevention-drug-lenacapavir-f243eb90c0bc6e595c8efa527e7c6b23 South Africa is home to more people living with HIV than any other country in the world, over 8 million, and for decades, the standard prevention method has been a daily oral pill that many people struggle to take consistently. That may be changing. In June 2026, South Africa became one of the first countries to officially roll out… Read more »<\/a><\/p>\n","protected":false},"author":331,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7341","post","type-post","status-publish","format-standard","hentry","category-article"],"_links":{"self":[{"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/posts\/7341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/users\/331"}],"replies":[{"embeddable":true,"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/comments?post=7341"}],"version-history":[{"count":1,"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/posts\/7341\/revisions"}],"predecessor-version":[{"id":7342,"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/posts\/7341\/revisions\/7342"}],"wp:attachment":[{"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/media?parent=7341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/categories?post=7341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/baileyonlineclassroom.com\/middleeastandnorthafricablog\/wp-json\/wp\/v2\/tags?post=7341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}